Abstract
The relationship between TaqI A dopamine D2 receptor (DRD 2) polymorphism and therapeutic response to bromperidol, a selective dopamine antagonist, was investigated in 30 acutely exacerbated schizophrenic inpatients. Patients were treated with bromperidol 6–18 mg/day for 3 weeks. Clinical symptoms were evaluated by the Brief Psychiatric Rating Scale (BPRS) before and 3 weeks after the treatment. The TaqI A genotypes were determined with the PCR method. There was no significant difference in the percentage improvement of total BPRS or 5-subgrouped symptoms (positive, negative, anxiety-depression, excitement and cognitive symptoms) after the 3-week treatment between the patients with A1 alleles (n=18) and those with no A1 allele (n=12). Although the present study is preliminary, it is suggested that the TaqI A DRD 2 polymorphism is not associated with therapeutic response to bromperidol in schizophrenic patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Additional information
Received: 27 September 2000 / Accepted: 10 January 2001
Rights and permissions
About this article
Cite this article
Suzuki, A., Kondo, T., Mihara, K. et al. Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report. European Archives of Psychiatry and Clinical Neurosciences 251, 57–59 (2001). https://doi.org/10.1007/s004060170053
Issue Date:
DOI: https://doi.org/10.1007/s004060170053